Provided by Tiger Trade Technology Pte. Ltd.

SCYNEXIS Inc

5.10
-0.1200-2.30%
Post-market: 5.100.00000.00%19:30 EDT
Volume:35.18K
Turnover:183.62K
Market Cap:50.64M
PE:-3.82
High:5.41
Open:5.29
Low:5.05
Close:5.22
52wk High:10.48
52wk Low:3.53
Shares:9.93M
Float Shares:7.36M
Volume Ratio:0.51
T/O Rate:0.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3352
EPS(LYR):-1.3793
ROE:-18.38%
ROA:-20.82%
PB:0.76
PE(LYR):-3.70

Loading ...

SCYNEXIS grants new VP stock options for 125,000 shares at $0.93, plus 20,000 RSUs

Reuters
·
May 07

Scynexis Announces Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 07

Press Release: SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
May 07

Scynexis files to sell 87M shares of common stock for holders

TIPRANKS
·
May 02

Scynexis Inc - Selling Stockholders Offer 87,000,000 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
May 02

SCYNEXIS announces special shareholder meeting

Reuters
·
Apr 18

SCYNEXIS CEO David Angulo Gonzalez buys common shares for $0.1 million

Reuters
·
Apr 02

SCYNEXIS buys PXL-770 asset from Poxel for USD 8 million upfront

Reuters
·
Apr 01

SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease

MT Newswires Live
·
Mar 31

Poxel announces sale of PXL770 to Scynexis for up to $196M

TIPRANKS
·
Mar 31

Press Release: Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

Dow Jones
·
Mar 31

Scynexis Announces $40.0 Million Private Placement

THOMSON REUTERS
·
Mar 31

Scynexis Inc - Estimates Funds Will Support Operations Into Mid-2029

THOMSON REUTERS
·
Mar 31

Press Release: SCYNEXIS Announces $40.0 Million Private Placement

Dow Jones
·
Mar 31

Scynexis Completes Transformative Acquisition of Pxl-770, an Innovative, Highly Selective, Direct Ampk Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (Adpkd)

THOMSON REUTERS
·
Mar 31

Scynexis Inc - to Pay $8 Mln Upfront, up to $188 Mln in Milestones for Acquisition

THOMSON REUTERS
·
Mar 31

Scynexis Inc - Phase 2 Study of Scy-770 in Adpkd to Begin in Q4 2026

THOMSON REUTERS
·
Mar 31

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

GlobeNewswire
·
Mar 31

Scynexis Reports Full Year 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Mar 05

Press Release: SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 05